2019年美国风湿病学会/脊柱炎协会/脊柱关节炎研究治疗网络对强直性脊柱炎和非放射学中轴型脊柱关节炎治疗建议的更新
该指南更新了2015年关于强直性脊柱炎(AS)和非放射学中轴型脊柱关节炎(SpA)的药物治疗建议,采用系统文献回顾和GRADE方法制定。推荐TNFi作为首选生物制剂,Secukinumab或Ixekizumab用于TNFi原发无应答者,不推荐低剂量甲氨蝶呤联用TNFi、严格达标治疗或生物制剂减停。
要点
- TNFi推荐作为首个生物制剂,优于Secukinumab或Ixekizumab。
- 对首个TNFi原发无应答者,推荐Secukinumab或Ixekizumab而非第二种TNFi。
- 不推荐低剂量甲氨蝶呤与TNFi联用、严格达标治疗或稳定期生物制剂减停。
核心结论
- 对于AS和非放射学中轴型SpA,推荐TNFi作为首个生物制剂,优于Secukinumab或Ixekizumab。
- 对首个TNFi原发无应答者,推荐Secukinumab或Ixekizumab而非第二种TNFi。
- 不推荐低剂量甲氨蝶呤与TNFi联用、严格达标治疗策略或稳定期生物制剂减停。
研究设计与样本
- 基于2015年指南的20个药物治疗临床问题更新系统文献回顾,并新增26个关于药物治疗、达标治疗和影像学的问题。
- 采用GRADE方法评估证据质量并制定推荐,要求投票小组至少70%同意。
主要发现
- TNFi、Secukinumab和Ixekizumab优于Tofacitinib。
- 柳氮磺吡啶仅推荐用于TNFi禁忌时持续外周关节炎。
- 对于疾病活动性不明确者,脊柱或骨盆MRI可辅助评估。
- 不推荐常规连续脊柱X线监测放射学变化。
关键数值与推荐
- TNFi推荐作为首个生物制剂,优于Secukinumab或Ixekizumab。
- 对首个TNFi原发无应答者,推荐Secukinumab或Ixekizumab而非第二种TNFi。
- 不推荐低剂量甲氨蝶呤与TNFi联用。
- 不推荐严格达标治疗策略。
- 不推荐稳定期生物制剂减停或减量。
临床怎么用
- 临床选择首个生物制剂时优先选用TNFi。
- TNFi原发无应答者应换用Secukinumab或Ixekizumab而非第二种TNFi。
- 避免低剂量甲氨蝶呤与TNFi联用及严格达标治疗策略。
- 稳定期患者不应减停生物制剂。
- 疾病活动性不明确时可借助脊柱或骨盆MRI评估。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). METHODS: We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on pharmacologic treatment, treat-to-target strategy, and use of imaging. New questions addressed the use of secukinumab, ixekizumab, tofacitinib, tumor necrosis factor inhibitor (TNFi) biosimilars, and biologic tapering/discontinuation, among others. We used the Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations and required at least 70% agreement among the voting panel. RESULTS: Recommendations for AS and nonradiographic axial SpA are similar. TNFi are recommended over secukinumab or ixekizumab as the first biologic to be used. Secukinumab or ixekizumab is recommended over the use of a second TNFi in patients with primary nonresponse to the first TNFi. TNFi, secukinumab, and ixekizumab are favored over tofacitinib. Co-administration of low-dose methotrexate with TNFi is not recommended, nor is a strict treat-to-target strategy or discontinuation or tapering of biologics in patients with stable disease. Sulfasalazine is recommended only for persistent peripheral arthritis when TNFi are contraindicated. For patients with unclear disease activity, spine or pelvis magnetic resonance imaging could aid assessment. Routine monitoring of radiographic changes with serial spine radiographs is not recommended. CONCLUSION: These recommendations provide updated guidance regarding use of new medications and imaging of the axial skeleton in the management of AS and nonradiographic axial SpA.
引用
- Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019. PMID: 31436026. doi:10.1002/acr.24025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。